Foreverland Food | $6,956,279 | (Mar 24, 2026)
Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Hamilton AI | $7,500,000 | (Mar 24, 2026)
Flourish Care | $5,700,000 | (Mar 24, 2026)
Interloom | $16,500,000 | (Mar 24, 2026)
eternal.ag | $9,271,160 | (Mar 24, 2026)
EGIDE | $9,266,200 | (Mar 24, 2026)
Cleavr | $1,158,600 | (Mar 24, 2026)
SPARK Microsystems | $12,364,525 | (Mar 24, 2026)
JAAQ | $17,416,100 | (Mar 24, 2026)
CisLunar Industries | $2,600,000 | (Mar 24, 2026)